帕金森病评估的远程临床决策支持工具,使用结合人工智能和临床知识的新方法来评估帕金森病
Harel Rom1,2, Ori Peleg1,3, Yovel Rom4
1Laboratory of Early Markers of Neurodegeneration, Neurological Institute, Tel Aviv Sourasky Medical Center, 6 Weizmann Street, Tel Aviv, 64239, Israel.
BMC medical informatics and decision making
|August 7, 2025
概括
这项研究表明,人工智能 (AI) 可以通过分析家庭视频中的面部表情来检测帕金森病 (PD). 这种人工智能工具对早期PD查和诊断充满希望.
科学领域:
- 神经学 神经学
- 人工智能的人工智能
- 医疗成像医学成像
背景情况:
- 通过早期检测可以改善帕金森病 (PD) 的诊断.
- 面部表情减少是PD的一个关键指标.
- 人工智能图像处理为PD检测提供了一个潜在的非侵入性工具.
研究的目的:
- 评估图像对文本人工智能系统在识别PD患者中的灵敏度.
- 评估AI与PD相关的面部表情描述匹配面部图像的能力.
- 确定AI作为PD检测临床决策支持工具的有效性.
主要方法:
- 收集了67名PD患者和52名健康对照者的面部图像.
- 开发了PD面部特征的描述性句子.
- 利用OpenAI的CLIP模型来生成图像-文本概率得分.
- 根据MDS-UPDRS得分,使用XGBoost模型进行PD患者识别.
主要成果:
- 基于面部表情,AI实现了0.78±0.05的AUC来识别PD患者.
- 患有轻微面部症状的患者的表现更高 (AUC = 0.87 ± 0.04).
- 人工智能显示了与所有MDS-UPDRS组件的显著相关性 (r > 0.23,p < 0.0001).
结论:
- 先进的人工智能可用于PD诊断中的临床决策支持工具.
- 这种AI方法为家庭PD查提供了一种新的方法.
- 人工智能有效地将临床知识转化为实际的查算法.
更多相关视频
08:36The Immersive Cleveland Clinic Virtual Reality Shopping Platform for the Assessment of Instrumental Activities of Daily Living
Published on: July 28, 2022
3.9K
06:32Author Spotlight: Automated Deep Brain Stimulation for Parkinson's Disease - Exploring the Possibilities and Challenges of Home Monitoring
Published on: July 14, 2023
1.4K
相关概念视频
01:24Parkinson's Disease: Treatment
380
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
380
01:15Parkinson's Disease: Overview
708
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
708